1031 related articles for article (PubMed ID: 32467995)
41. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
Shen J; Zhou J; Chen GQ; Xiu ZL
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
[No Abstract] [Full Text] [Related]
42. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
43. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
44. CRISPR-Cas9: from Genome Editing to Cancer Research.
Chen S; Sun H; Miao K; Deng CX
Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
[TBL] [Abstract][Full Text] [Related]
45. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
46. CRISPR system for genome engineering: the application for autophagy study.
Cui J; Chew SJL; Shi Y; Gong Z; Shen HM
BMB Rep; 2017 May; 50(5):247-256. PubMed ID: 28288698
[TBL] [Abstract][Full Text] [Related]
47. CRISPR-Cas9: A New Addition to the Drug Metabolism and Disposition Tool Box.
Karlgren M; Simoff I; Keiser M; Oswald S; Artursson P
Drug Metab Dispos; 2018 Nov; 46(11):1776-1786. PubMed ID: 30126863
[TBL] [Abstract][Full Text] [Related]
48. Genome Editing by CRISPR/Cas9 in Sorghum Through Biolistic Bombardment.
Liu G; Li J; Godwin ID
Methods Mol Biol; 2019; 1931():169-183. PubMed ID: 30652290
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
50. A new era of gene editing for the treatment of human diseases.
Kc M; Steer CJ
Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
[TBL] [Abstract][Full Text] [Related]
51. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches.
Ahmed MZ; Badani P; Reddy R; Mishra G
J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111
[TBL] [Abstract][Full Text] [Related]
52. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
Duroux-Richard I; Giovannangeli C; Apparailly F
Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
[No Abstract] [Full Text] [Related]
53. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
Li Y; Glass Z; Huang M; Chen ZY; Xu Q
Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
Hong KQ; Liu DY; Chen T; Wang ZW
World J Microbiol Biotechnol; 2018 Sep; 34(10):153. PubMed ID: 30269229
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic Genome Editing by CRISPR/Cas9-Mediated Strategy to Cure Genetic Disorders in Humans: Guide for Molecular Surgeons.
Ergoren MC; Idlibi R
Crit Rev Eukaryot Gene Expr; 2019; 29(5):387-399. PubMed ID: 32421996
[TBL] [Abstract][Full Text] [Related]
56. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
57. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
58. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
[TBL] [Abstract][Full Text] [Related]
59. CRISPR-Cas9 System: Opportunities and Concerns.
Vasiliou SK; Diamandis EP; Church GM; Greely HT; Baylis F; Thompson C; Schmitt-Ulms G
Clin Chem; 2016 Oct; 62(10):1304-11. PubMed ID: 27551006
[No Abstract] [Full Text] [Related]
60. [Recent developments in enhancing the efficiency of CRISPR/Cas9- mediated knock-in in animals].
Li GL; Yang SX; Wu ZF; Zhang XW
Yi Chuan; 2020 Jul; 42(7):641-656. PubMed ID: 32694104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
